iMAB
Phase 3Monoclonal antibody
iMAB is one of 5 small molecule programs targeting Androgen Deprivation Therapy. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Androgen Deprivation Therapy
#DrugCompanyPhaseTrials
1Nubeqa
BayerPhase 2
Orgovyx
Sumitomo Pharma America, Inc.Phase 2
Lupron
EEastern Cooperative Oncology Group
Phase 2
iMAB
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Phase 3
Rezvilutamide
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Androgen Deprivation Therapy1 trial
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT05974774·1,600 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iMAB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details